Nurdan KOTEVOĞLU, Sibel KARŞIDAĞ, Miruna Florentina ATEŞ, Şevki ŞAHİN, Nilgün ÇINAR

Validation and reliability study of the Turkish version of the Neuroquality of Life (Neuro-QoL)-Stigma Scale for neurological disorders

Background/aim: Stigma can be defined as a negative perception of chronically ill patients by their relatives or by society, or a similarself-perception by the patients themselves. We aimed to validate the Turkish version of the Neuroquality of Life (Neuro-QoL)-StigmaScale for neurologic diseases.Materials and methods: Forms were filled out by a total of 152 randomized patients under regular follow-up in the outpatient clinic (29polyneuropathy, 25 epilepsy, 23 stroke, 24 tension-type headache, 28 multiple sclerosis, 27 Parkinson disease). The forms consisted ofthe Beck Depression Inventory (BDI), Beck Anxiety Inventory (BAI), WHOQOL-BREF quality of life scale, the Multidimensional Scaleof Perceived Social Support (MSPSS), the General Self-Efficacy (GSE) scale, and the Neuro-QoL-Stigma scale.Results: The internal consistency of the Neuro-QoL-Stigma scale showed Cronbach’s α coefficients of 0.95 for all groups. The meanscores of the stigma scales were 33.42 ± 13.91 (min–max: 24–87). There were strong negative correlations between high stigma scoresand GSE-T, MSPSS-T, and WHOQOL-BREF, and a positive correlation with the BDI and BAI.Conclusion: The Turkish version of Neuro-QoL-Stigma has satisfactory content validity and high internal consistency. Neuro-QoLStigma is suitable for understanding stigmatization in different neurological disorders in the Turkish population. The scale is availablefor use at http://www.healthmeasures.net/explore-measurement-systems/neuro-qol.

PDF

___

1. Goffman E. Stigma. Notes on the Management of Spoiled Identity. Englewood Cliffs, NJ, USA: Prentice Hall; 1963.
2. Link BG, Phelan JC. Conceptualizing stigma. Annu Rev Sociol 2001; 27: 363-385.
3. Major B, O’Brien LT. The social psychology of stigma. Annu Rev Psychol 2005; 56: 393-421.
4. Berkman LF, Kawachi I. A historical framework for social epidemiology. In: Berkman LF, Kawachi I, editors. Social Epidemiology. New York, NY, USA: Oxford University Press; 2000. pp. 3-12.
5. Kabay SC, Toğrol E, Mestan E. Nörolojik hastalıklarda stigmatizasyon ve ölçümü. Turkish Journal of Neurology 2014; 20: 91-99 (in Turkish).
6. Ben-Zeev D, Young MA, Corrigan PW. DSM-V and the stigma of mental illness. J Ment Health 2010; 19: 318-27.
7. Rao D, Choi SW, Victorson D, Bode R, Peterman A, Heinemann A, Cella D. Measuring stigma across neurological conditions: the development of the Stigma Scale for Chronic Illness (SSCI). Qual Life Res 2009; 18: 585-595.
8. Jacoby A, Snape D, Baker GA. Epilepsy and social identity: the stigma of a chronic neurological disorder. Lancet Neurol 2005; 4: 171-178.
9. Aydemir N, Özkara Ç, Canbeyli R, Tekcan A. Changes in quality of life and self-perspective related to surgery in patients with temporal lobe epilepsy. Epilepsy Behav 2004; 5: 735-742.
10. Pazarcı NK, Yükselen NP, Aydın Ş, Acar ZÜ, Örken DN. Validation and reliability study of the Turkish version of the stigma scale of epilepsy. Arch Neuropsychiatry 2017; 54: 295- 300.
11. Ozdilek B, Gunal DI. Motor and non-motor symptoms in Turkish patients with Parkinson’s disease affecting family caregiver burden and quality of life. J Neuropsychiatry Clin Neurosci 2012; 24: 478-483.
12. Aydemir Ö. Sağlıkta yaşam kalitesinin klinikte kullanımı. Turkish Journal of Neurology-Special Topics 2014; 20: 5-9 (in Turkish).
13. Correia H, Pérez B, Arnold B, Wong AW, Lai JS, Kallen M, Cella D. Spanish translation and linguistic validation of the quality of life in neurological disorders (Neuro-QoL) measurement system. Qual Life Res 2015; 24: 753-756.
14. Gershon RC, Lai JS, Bode R, Choi S, Moy C, Bleck T, Miller D, Peterman A, Cella D. Neuro-QOL: Quality of life item banks for adults with neurological disorders: item development and calibrations based upon clinical and general population testing. Qual Life Res 2012; 21: 475-486.
15. Perez L, Huang J, Jansky L, Nowinski C, Victorson D, Peterman A, Cella D. Using focus groups to inform the Neuro-QOL measurement tool: exploring patient-centered, health-related quality of life concepts across neurological conditions. J Neurosci Nurs 2007; 39: 342-353.
16. National Institute of Neurological Disorders and Stroke. User Manual for the Quality of Life in Neurological Disorders (Neuro-QoL) Measures, Version 2.0. Bethesda, MD, USA: National Institute of Neurological Disorders and Stroke; 2015.
17. Güngen C, Ertan T, Eker E, Yaşar R, Engin F. Standardize Mini Mental Test’in Türk toplumunda hafif demans tanısında geçerlilik ve güvenirliliği. Türk Psikiyatri Dergisi 2002; 13: 273- 282 (in Turkish).
18. WHOQOL Group. Development of the WHOQOL: Rationale and current status. Int J Ment Health 1994; 23: 24-56.
19. World Health Organization. Quality of Life Group: WHOQOLBREF Introduction. Administration and Scoring. Field Trial Version. Geneva, Switzerland: WHO; 1996.
20. Eser E, Fidaner H, Fidaner C, Eser SY, Elbi H, Göker E. WHOQOL-100 ve WHOQOL-BREEF’in Psikometrik Özellikleri. 3P Dergisi 1999; 7: 23-40.
21. Beck AT, Word CH, Mendelson M, Mock J, Erbaugh J. An inventory for measuring depression. Arch Gen Psyc 1961; 4: 561-571.
22. Hisli N. Beck Depresyon Envanterinin geçerliliği üzerine bir çalışma. Türk Psikoloji Dergisi 1988; 6: 118-126 (in Turkish).
23. Hisli N. Beck Depresyon Envanterinin üniversite öğrencileri için geçerlilik ve güvenilirliği. Türk Psikoloji Dergisi 1989; 7: 3-13 (in Turkish).
24. Beck AT, Epstein N, Brown G, Steer RA. An inventory for measuring clinical anxiety: psychometric properties. J Consult Clin Psychol 1988; 56: 893-897.
25. Ulusoy M, Sahin NH, Erkmen H. Turkish version of the Beck Anxiety Inventory: Psychometric properties. J Cogn Psychother 1998; 12: 163-172.
26. Schwarzer R, Jerusalem M. Generalized Self-Efficacy Scale. In: Weinman J, Wright S, Johnston M, editors. Measures in Health Psychology: A User’s Portfolio. Windsor, UK: NFER-Nelson; 1995. pp. 35-37.
27. Yıldırım F, İlhan İÖ. The validity and reliability of the General Self-Efficacy Scale-Turkish Form. Turkish Journal of Psychiatry 2010; 21: 301-308.
28. Zimet GD, Dahlem NW, Zimet SG, Farley GK. The Multidimensional Scale of Perceived Social Support. J Pers Assess 1988; 52: 30-41.
29. Eker D, Arkar H, Yaldız H. Factorial structure, validity, and reliability of revised form of the Multidimensional Scale of Perceived Social Support. Turkish Journal of Psychiatry 2001; 12: 17-25.
30. Ablon J. The nature of stigma and medical conditions. Epilepsy Behav 2002; 3: 2-9.
31. Ak PD, Ataklı D, Yüksel B, Sarı H. Stigmatization and social impacts of epilepsy in Turkey. Epilepsy Behav 2015; 50: 50-54.
32. Aydemir N, Jacoby A, Ozkara C. Predictors of positive and negative attitudes toward their condition in Turkish individuals with epilepsy. Seizure 2012; 21: 385-390.
33. Yeni K, Tulek Z, Bebek N. Factors associated with perceived stigma among patients with epilepsy in Turkey. Epilepsy Behav 2016; 60: 142-148.
34. Victorson D, Cavazos JE, Holmes GL, Reder AT, Wojna V, Nowinski C, Miller D, Buono S, Mueller A, Moy C et al. Validity of the Neurology Quality of Life (Neuro-QoL) measurement system in adult epilepsy. Epilepsy Behav 2014; 31: 77-84.
35. Ma HI, Saint-Hilaire M, Thomas CA, Tickle-Degnen L. Stigma as a key determinant of health related quality of life in Parkinson’s disease. Qual Life Res 2016; 25: 3037-3045.
36. Nowinski CJ, Siderowf A, Simuni T, Wortman C, Moy C, Cella D. Neuro-QoL health-related quality of life measurement system: validation in Parkinson’s disease. Mov Disord 2016; 31: 725-733.
37. Anagnostouli M, Katsavos S, Artemiadis A, Zacharis M, Argyrou P, Theotoka I, Christidi F, Zalonis I, Liappas I. Determinants of stigma in a cohort of Hellenic patients suffering from multiple sclerosis: a cross-sectional study. BMC Neurol 2016; 16: 101.
38. Cook JE, Germano AL, Stadler G. An exploratory investigation of social stigma and concealment in patients with multiple sclerosis. Int J MS Care 2016; 18: 78-84.
39. Miller DM,Bethoux F, Victorson D, Nowinski CJ, Buono S, Lai JS, Wortman K, Burns JL, Moy C, Cella D. Validating NeuroQoL short forms and targeted scales with persons who have multiple sclerosis. Mult Scler 2016; 22: 830-841.
40. Sarfo FS, Nichols M, Qanungo S, Teklehaimanot A, Singh A, Mensah N, Saulson R, Gebregziabher M, Ezinne U, Owolabi M et al. Stroke-related stigma among West Africans: patterns and predictors. J Neurol Sci 2017; 375: 270-274.
41. Prakash S. Patients with tension-type headaches feel stigmatized. Ann Indian Acad Neurol 2016; 19: 112-114.
42. Young WB, Park JE, Tian IX, Kempner J. The stigma of migraine. PLoS One 2013; 8: e54074.
43. Mendes Á, Sousa L, Sequeiros J, Clarke A. Discredited legacy Stigma and familial amyloid polyneuropathy in Northwestern Portugal. Soc Sci Med 2017; 182: 73-80.